Switzerland's strict vaccine injury reviews leave claimants in limbo

Switzerland has taken a far stricter approach to recognising vaccine-related injuries than neighbouring Germany. While German authorities confirmed nearly 600 cases by April 2025, Swiss officials had approved just two by September of the same year. The slow process has left many claimants frustrated by the lack of clarity from the Federal Office of Public Health (FOPH).

Germany's compensation system processed over 14,000 applications by April 2025, approving 573 cases of permanent damage—an approval rate of 6.2%. Earlier figures from May 2023 showed only 325 recognitions out of 7,984 claims, but the numbers have since risen. Local supply offices handle each case, though specific criteria remain unclear.

In contrast, Switzerland's FOPH has approved just two of around 300 claims. The first successful case resulted in 12,500 Swiss francs for pain and suffering and 1,360 francs in damages. The office examines each claim individually, systematically ruling out other possible causes before considering vaccination as a factor. This cautious method has drawn criticism, as affected individuals describe the delays and silence as distressing.

Establishing a direct link between vaccination and health issues remains challenging. Approval studies for Pfizer-BioNTech and Moderna vaccines found no serious side effects, as severe reactions are rare. Yet, the disparity between Germany's and Switzerland's recognition rates highlights differing national approaches to compensation.

The FOPH's strict review process means most Swiss claimants face lengthy waits with uncertain outcomes. With only two approved cases so far, the system remains far more restrictive than Germany's. Those affected continue to seek answers as the office maintains its cautious stance.